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Background. Redox active substances (e.g., Thioredoxin-1, Macrophage Migration Inhibitory Factor) seem to be central hubs in
the septic inﬂammatory process. Materials and Methods. Blood samples from patients with severe sepsis or septic shock (n = 15)
were collected at the time of sepsis diagnosis (t0), and 24 (t24) and 48 (t48) hours later; samples from healthy volunteers
(n = 18) were collected once; samples from postoperative patients (n = 28) were taken one time immediately after surgery.
In all patients, we measured plasma levels of IL-6, TRX1 and MIF. Results. The plasma levels of MIF and TRX1 were signiﬁcantly
elevated in patients with severe sepsis or septic shock. Furthermore, TRX1 and MIF plasma levels showed a strong correlation (t0:
rsp = 0.720,ρ = 0.698/t24: rsp = 0.771,ρ = 0.949). Conclusions. Proinﬂammatory/∼oxidative and anti-inﬂammatory/∼oxidative
agents show a high correlation in order to maintain a redox homeostasis and to avoid the harmful eﬀects of an excessive
inﬂammatory/oxidative response.
1.Introduction
Severe sepsis, septic shock, and the resulting multiple organ
failure/dysfunction syndrome represent an ongoing chal-
lenge in intensive care units [1–5]. With mortality ranging
from 40% to 70%, septic shock is the most common cause
of death in intensive care medicine [2, 6]. Despite intensive
basic research and clinical studies, the pathophysiology of
sepsis is still poorly understood. Inﬂammation leads to
oxidative stress because of the production of reactive oxygen
species (ROS). Oxidative stress is a major contributing
factor to the high mortality rates associated with several
diseases such as endotoxic shock. Immune cells therefore
need adequate levels of antioxidant defenses in order to
avoid harmful eﬀects of an excessive ROS production and
to keep a well-balanced redox homeostasis. In this context,
two substances have recently become of great interest: (1)
Macrophage Migration Inhibitory Factor (MIF), a proin-
ﬂammatory protein, which is released by immune cells and
shows elevated levels in sepsis syndrome, as well as (2)
Human Thioredoxin-1 (TRX1), a potent antioxidant that
modulates inﬂammation, cell growth, and apoptosis, which2 Mediators of Inﬂammation
seems to counteract the proinﬂammatory and pro-oxidant
eﬀects of MIF [7–9]. Therefore, these two biomarkers appear
to be central hubs in the inﬂammatory setting and are
therefore of great interest. However, no suﬃcient knowledge
exists about the role of these key mediators in severe sepsis or
septic shock. The aims of this study were therefore twofold:
(1) to assess the plasma levels of each parameter in diﬀerent
inﬂammatory settings (healthy volunteers, postoperative,
and septic patients) and (2) to establish whether plasma
levels of TRX1 and MIF correlate with each other.
2.MaterialsandMethods
The observational clinical study was approved by the local
ethics committee and was conducted in the surgical and
medical intensive care units of the University Hospitals of
Heidelberg and Mannheim, Germany. All study and control
patients or their legal designees signed written informed
consent. In total, 61 individuals in three groups were
enrolled in the study (Table 1). The three groups included
15 patients with severe sepsis or septic shock (referred to as
the septic group), 28 patients after major abdominal surgery
(the postoperative group), and 18 healthy volunteers (the
volunteer group). The 15 patients were classiﬁed as having
severe sepsis or septic shock based on the criteria of the
International Sepsis Deﬁnitions Conference [10]. Patients
wereeligibleforenrollmentwithanonsetofsepsissyndrome
≤24hours.Theinitialblooddrawwasalsoperformedwithin
this period. In contrast, patients with an onset of sepsis
syndrome >24 hours were excluded from the study. The
management of patients with severe sepsis or septic shock in
the intensive care unit included early goal-directed therapy
(according to Rivers and colleagues [11]), elimination of
the septic focus, and broad-spectrum antibiotics [12, 13].
The second group included 28 patients undergoing major
abdominal surgery, with negative parameters for systemic
inﬂammatory response syndrome (Table 1). As a control
group, we chose 18 healthy young volunteers without any
signs of infection (Table 1). Blood samples from patients
with severe sepsis were collected within 24 hours after the
diagnosis of sepsis, and also 24 and 48 hours later. In the
septic group, severity of illness was estimated using the Acute
Physiology and Chronic Health Evaluation (APACHE) II
score as well as the Sequential Organ Failure Assessment
(SOFA) score and the Simpliﬁed Acute Physiology Score
(SAPS) II. Patients with sepsis were re-evaluated for survival
90 days after enrollment in the study. This evaluation was
performed using available hospital records. In case of the
patient’s discharge from the hospital, the family doctor was
contacted. If necessary, we furthermore got in contact with
the patient himself. Blood samples from the postoperative
group were collected once immediately after surgery, and
the samples from the volunteer group were taken one time.
After blood collection, plasma of all study participants was
immediately obtained by centrifugation, transferred into
cryotubes, and stored at −80
◦C until further processing.
Human Interleukin-6 (IL-6) was measured in order to deter-
mine the ongoing inﬂammatory response. Furthermore, the
Table 1: Baseline data of 15 patients in the septic group, 28 patients
in the postoperative group, and 18 individuals in the volunteer
group.
Septic group
Demographic data
Age, y 61.0 ± 13.7
Male sex 9 (60.0%)
Primary site of infection / septic focus
Lung 3 (20.0%)
Gastrointestinal tract 6 (40.0%)
Genitourinary tract 1 (6.7%)
Surgical site 3 (20.0%)
Other 2 (13.3%)
Outcome
Survivor 8 (53.3%)
Postoperative group
Demographic data
Age, y 62.3 ± 14.2
Male sex 15 (53.6%)
Primary site of surgery
Pancreas 13 (46.4%)
Colon 5 (17.9%)
Liver 2 (7.1%)
Genitourinary 3 (10.7%)
Other abdominal 5 (17.9%)
Volunteer group
Demographic data
Age 34.5 ± 8.6
Male sex 10 (55.6%)
Data are presented by number (%), except for age (mean ± standard
deviation).
activation of the redox system was evaluated. Therefore, we
measured plasma levels of Human Thioredoxin-1 (TRX1)
and Macrophage Migration Inhibitory Factor (MIF). We
used ELISA kits to determine plasma concentrations of
Interleukin-6 (IL-6, R&D Systems, Minneapolis, MN, USA),
Human Thioredoxin-1 (Human TRX1, LabFrontier Co.,
Ltd, Seoul, Korea), and Macrophage Migration Inhibitory
Factor (Human MIF, RayBiotech, Inc., Norcross, GA, USA)
according to the manufacturers’ instructions.
All assays were performed in duplicate. The result-
ing study data were entered into an electronic database
(Microsoft Excel 2002, Microsoft Corporation, Redmond,
WA, USA) and evaluated using SPSS software (Statistical
Product and Services Solutions, Version 16.0, SPSS Inc,
Chicago, IL, USA). Categorical data were summarized by
means of absolute and relative frequencies (counts and
percentages). Quantitative data were summarized using the
number of observations, mean and standard deviation,
minimum, median with quartiles, or diﬀerences of the
quartiles and maximum. Wherever appropriate, data were
visualized using box-and-whisker plots. The Kolmogorov-
Smirnov test was applied to check for normal distribution.
Duetoabnormallydistributeddata,nonparametricmethodsMediators of Inﬂammation 3
for evaluation were used (chi-square test for categorical data,
Mann-Whitney U-test as well as Wilcoxon test for contin-
uous data). Correlation analysis was performed using two-
sided Spearman’s rank correlation test as well as Pearson’s
product-moment correlation test. A P value <. 05 was
considered statistically signiﬁcant. Concerning symbolism
and higher orders of signiﬁcance: P<. 05:∗, P<. 01:∗∗,
P<. 001:∗∗∗.
3. Results
Age and sex of patients in the septic (61 years; 9 male
sex) and postoperative (62 years; 15 male sex) groups were
comparable (Table 1). In the septic group, patients who
survived or died showed no signiﬁcant diﬀerences in their
demographic data (data not shown). In contrast, healthy
volunteers (35 years; 10 male sex) were signiﬁcantly younger
comparedwiththesepticandpostoperativegroups(Table 1).
In the septic group, 8 of 15 patients (53.3%) survived
(Table 1). No one in the postoperative or volunteer groups
died during the study. The primary site of infection in
the septic group was the gastrointestinal tract (6 patients,
40.0%). Furthermore, the septic focus was found to be in
the respiratory tract (3 patients, 20%) or dedicated as a
surgical complication (3 patients, 20%) (Table 1). A positive
culture from the site of infection was obtained in 67% of all
septic patients. In these patients, cultures were found to be
gram-negative in 70% and gram-positive in 30%. Patients
in the postoperative group primarily underwent surgery of
the pancreas, whereas surgeries of the colon, liver, and the
genitourinary tract were less frequent (Table 1).
Septic patients were considered to be severely injured
during the entire study period, as assessed by the APACHE
II, SOFA, and SAPS II score, but showed no signiﬁcant
diﬀerences between the surviving and nonsurviving sub-
groups of septic patients (Table 2). Plasma levels of IL-6 were
signiﬁcantly elevated at the onset of sepsis compared with
the postoperative and the volunteer groups (Figure 1 and
Table 3). Furthermore, plasma levels of IL-6 were signiﬁ-
cantly elevated in the postoperative group compared with
healthyvolunteers(Figure 1andTable 3).Inthesepticgroup,
the level of IL-6 decreased signiﬁcantly within 24 hours after
sepsis onset (t0 → t24: P = .021∗, t24 → t48: P =
.225, t0 → t48: P = .075), but still remained signiﬁcantly
higher than the volunteer group (t24: P<. 001∗∗∗, t48:
P<. 001∗∗∗)( Figure 1). Il-6 levels did not diﬀer between
the surviving and nonsurviving subgroup of septic patients
at any time (Table 2). The plasma levels of TRX1 were
signiﬁcantly elevated at the time of diagnosis of sepsis,
compared with levels in the postoperative and volunteer
groups (Figure 2 and Table 3). TRX1 plasma levels decreased
signiﬁcantly within 48 hours after sepsis onset (t0 → t24 :
P = .046
∗, t24 → t48 : P = .715, t0 → t48 :
P = .028
∗), but still remained signiﬁcantly elevated than
the volunteer group (t24 : P = .114,t48 : P = .042
∗).
In comparison to the postoperative group, TRX1 plasma
levels of septic patients failed scarcely to show a signiﬁcant
diﬀerence at t24, as well as t48 (t24 : P = .061, t48 : P =
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Figure 1: Comparison of Interleukin-6 (IL-6) in the volunteer,
postoperative, and septic groups at baseline and at 24 and 48 hours
in the septic group. Concentrations of Interleukin-6 (IL-6; (pg/ml))
were measured from the sera of healthy volunteers (“Healthy”,
n = 18, white box), postoperative patients after major abdominal
surgery (“Post-OP”, n = 28, light grey box), and patients with sepsis
(“Sepsis”, n = 15, dark grey box), at t0 (measured once for the
volunteer group, immediately after surgery for the postoperative
group, and at the time of diagnosis of sepsis for the sepsis group).
In addition, for the septic group, the 2 other times of data collection
are represented, t24 and t48 for 24 and 48 hours, respectively, after
the diagnosis of sepsis. Data in box plots are given as median,
25th percentile, 75th percentile, and the 1.5 interquartile range.
Outliers are shown in form of circles (1.5–3 interquartile ranges
above 75th percentile or below 25th percentile) or rectangles (>3
interquartilerangesabove75thpercentileorbelow25thpercentile).
Abbreviations: IL-6, Interleukin-6.
.069) (Figure 2). TRX1 plasma levels did not diﬀer between
the postoperative and volunteer groups (TRX1: P = .458)
(Figure 2 and Table 3). Furthermore, between the surviving
andnonsurvivingsubgroupsofsepticpatients,TRX1plasma
levels did not show any signiﬁcant diﬀerence (Table 2). The
plasmalevelsofMIFweresigniﬁcantlyelevatedatthetimeof
diagnosis of sepsis, compared with levels in the postoperative
and volunteer groups (Figure 3 and Table 3). MIF plasma
levels decreased signiﬁcantly within 48 hours after sepsis
onset (t0 → t24: P = .050∗, t24 → t48: P = .893, t0 → t48:
P = .028∗), but still remained signiﬁcantly elevated than
the volunteer group (t24: P = .030∗, t48: P = .048∗)
and the postoperative group (t24: P = .023∗, t48: P =
.069) (Figure 3). MIF plasma levels did not diﬀer between
the postoperative and volunteer groups (MIF: P = .954)
(Figure 3 and Table 3). Furthermore, between the surviving
and nonsurviving subgroups of septic patients, MIF plasma
levels did not show any signiﬁcant diﬀerence (Table 2).
A correlation analysis using two-sided Spearman’s rank
correlation test, as well as Pearson’s product-moment cor-
relation test, indicated a strong correlation between TRX1
and MIF plasma levels in patients with severe sepsis or septic
shock especially at the onset of sepsis syndrome (t0: rsp =
0.720, ρ = 0.698) and 24 hours later (t24: rsp = 0.771,4 Mediators of Inﬂammation
Table 2: Comparison of IL-6, TRX1, and MIF plasma levels, as well as APACHE II, SAPS II, and SOFA scores in survivors and nonsurvivors
in the septic group at baseline and at 24 and 48 hours.
Survivor (n = 8) Nonsurvivor (n = 7) P-value
IL-6 (pg/ml)
t0 578.7; 451.4–579.9 576.1; 521.9–581.6 >.05
t24 262.2; 103.4–300.3 371.2; 153.6–553.7 >.05
t48 53.0; 41.0–79.6 51.7; 47.4–312.0 >.05
P-value t0-t24-t48 >.05 >.05
TRX1 (ng/ml)
t0 26.8; 14.2–44.7 57.5; 22.0–82.2 >.05
t24 25.8; 13.4–47.8 22.9; 16.3–28.0 >.05
t48 12.9; 9.5–16.1 23.8; 21.1–27.9 >.05
P-value t0-t24-t48 >.05 >.05
MIF (pg/ml)
t0 1645.8; 345.1–4078.7 1821.1; 971.9–3147.6 >.05
t24 624.7; 396.3–1899.5 889.0; 432.4–1467.3 >.05
t48 421.8; 315.3–692.7 951.1; 425.8–1469.0 >.05
P-value t0-t24-t48 >.05 .05∗
APACHE II (points)
t0 43.0; 35.0–45.0 33.0; 32.5–37.0 >.05
t24 35.0; 29.5–40.8 43.0; 38.8–45.0 >.05
t48 34.0; 23.5–38.5 35.0; 35.0–36.0 >.05
P-value t0-t24-t48 >.05 >.05
SOFA (points)
t0 13.0; 11.0–15.0 16.5; 15.0–18.0 >.05
t24 13.0: 11.5–15.5 16.5; 14.3–18.0 >.05
t48 14.0: 12.0–15.0 18.0; 9.0–18.0 >.05
P-value t0-t24-t48 >.05 >.05
SAPS II (points)
t0 60.5; 54.8–66.3 81.0; 72.3–89.3 >.05
t24 73.0; 60.0–77.0 76.5; 66.0–84.5 >.05
t48 63.0; 57.5–75.5 76.0; 71.0–90.0 >.05
P-value t0-t24-t48 >.05 >.05
Data are presented by median and interquartile range (Q1–Q3).
ρ = 0.949) (Figure 4). In contrast, between TRX1 and IL-
6 plasma levels as well as between MIF and IL-6 plasma
levels in septic patients, no signiﬁcant correlations could be
observed at the onset of sepsis (TRX/IL-6, t0: rsp = 0.143,
ρ = 0.106; MIF/IL-6, t0: rsp = 0.029, ρ = 0.127) and 24
hours later (TRX/IL-6, t24: rsp = 0.107, ρ = 0.087; MIF/IL-6,
t24: rsp = 0.310, ρ = 0.232).
4. Discussion
The present study demonstrates that proinﬂammatory/∼
oxidative (Macrophage Migration Inhibitory Factor, MIF) as
wellas anti-inﬂammatory/∼oxidative (HumanThioredoxin-
1, TRX1) agents are signiﬁcantly raised in patients with
severe sepsis and septic shock. Positive correlations between
these two mediators may suggest a linked role in the
pathophysiology of sepsis.
Severe sepsis as well as septic shock and related multiple
organ dysfunction syndrome is still the most common
cause of death in intensive care medicine [1–6]. Many of
the pathophysiological changes during sepsis are related to
inﬂammation [14]. Not surprisingly, diﬀerent markers of
systemic inﬂammation (e.g., IL-6) and mediators involved in
theredoxhomeostasis(e.g.,TRX1,MIF)aresigniﬁcantlyele-
vated during ongoing sepsis [15], whereas only IL-6 diﬀered
between patients after major abdominal surgery and healthy
volunteers. This reﬂects generalized infection during sepsis,
whilepatientsaftermajorabdominalsurgeryexperienceonly
a mild activation of their inﬂammatory system [16]. IL-
6 is released into the bloodstream after any kind of tissue
insult [17]. Therefore, IL-6 is the most commonly described
cytokine after surgery. Concentrations of IL-6 peak 24 hours
after the surgical procedure and return to the baseline value
in a few days in noninfected patients [18]. In accordance to
our investigation, IL-6 peak concentrations are reported to
be generally in the range of 200–300pg/ml [19]. The highest
IL-6 serum/plasma concentrations are reached during sepsis,
therefore it appears to be a good marker of the severity of
infection [20, 21]. (Human) Thioredoxin-1 (TRX1) is an
anti-inﬂammatory agent, whose anti-inﬂammatory eﬀects
are not yet completely understood. TRX1 is a redox-sensitive
moleculethathaspleiotropic cellulareﬀects,functioningasa
protective cellular antioxidant and regulator of transcription
factoractivity[22–27].TogetherwiththeTRX-reductaseand
NADPH, TRX1 represents a major intracellular reducing
agent containing a redox-active disulﬁde/dithiol within the
conserved active site sequence Cys-Gly-Pro-Cys, and there-
fore protecting cells from oxidative stress [22–27]. Beside
these antioxidative eﬀects, TRX1 plays an important role in
the modulation of the immune system by regulating DNA
bindingofseveraltranscriptionfactors(e.g.,p53,NFkappaB,Mediators of Inﬂammation 5
Table 3: Comparison of IL-6, TRX1, and MIF plasma levels in the volunteer, postoperative, and septic group at baseline.
Healthy (n = 18) Post-OP (n = 28) Sepsis (n = 15)
IL-6 (pg/ml) 0.0; 0.0–0.8 216.7; 48.8–360.5 577.7; 521.9–583.2
P-value
Healthy versus Post-OP: P<. 001∗∗∗
Healthy versus Sepsis: P<. 001∗∗∗
Post-OP versus Sepsis: P <.001∗∗∗
TRX1 (ng/ml) 11.0; 10.0–12.1 11.3; 9.6–15.6 34.0; 19.7–57.7
P-value
Healthy versus Post-OP: P = .458
Healthy versus Sepsis: P<. 001∗∗∗
Post-OP versus Sepsis: P <.001∗∗∗
MIF (pg/ml) 161.6; 148.5–214.0 156.4; 115.1–398.7 1821.1; 412.2–3708
P-value
Healthy versus Post-OP: P = .954
Healthy versus Sepsis: P = .005∗∗
Post-OP versus Sepsis: P<. 001∗∗∗
Data are presented by median and interquartile range (Q1–Q3).
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Figure 2: Comparison of Thioredoxin-1 (TRX1) measurements in
the volunteer, postoperative, and septic groups at baseline and at 24
and 48 hours in the septic group. Concentrations of Thioredoxin-1
(TRX1; (ng/ml)) were measured from the sera of healthy volunteers
(“Healthy,” n = 18, white box), postoperative patients after major
abdominal surgery (“Post-OP,” n = 28, light grey box), and patients
with sepsis (“Sepsis,” n = 15, dark grey box), at t0 (measured
once for the volunteer group, immediately after surgery for the
postoperative group, and at the time of diagnosis of sepsis for
the sepsis group). In addition, for the septic group, the two other
times of data collection are represented, t24 and t48 for 24 and
48 hours, respectively, after the diagnosis of sepsis. Data in box
plots is given as median, 25th percentile, 75th percentile, and the
1.5 interquartile range. Outliers are shown in form of circles (1.5-3
interquartile ranges above 75th percentile or below 25th percentile)
orrectangles(>3interquartilerangesabove75thpercentileorbelow
25th percentile). Abbreviations: TRX1, Thioredoxin-1.
activator protein-1) [28–30]. Several investigations have
shown that extracellular levels of TRX1 are increased in
conditions of oxidative stress and inﬂammation [7, 30–
39]. In accordance to these investigations, the present study
was able to demonstrate that plasma TRX1 levels were
signiﬁcantly higher in patients with sepsis compared to
healthy volunteers and postoperative patients. The elevated
plasma levels of TRX1 then most likely reﬂect the increased
oxidative stress in septic patients. In the literature, it was
demonstrated that increased TRX1 plasma levels induced
resistancetoharmfulconditionsinanimalmodels(e.g.,LPS-
induced acute hepatitis, cecal ligation, and puncture) [40–
47] due to the ability of TRX1 to relieve local oxidative
stress and to modulate neutrophiles extravasation into sites
of inﬂammation [48]. Furthermore, TRX1 seems to be able
to counteract the proinﬂammatory and pro-oxidant eﬀects
of Macrophage Migration Inhibitory Factor (MIF) [49].
MIF is another member of the TRX superfamily, but
functions as a classical proinﬂammatory cytokine [9].
Macrophage Migration Inhibitory Factor (MIF) activates T-
cells and macrophages, ampliﬁes the production of other
proinﬂammatory cytokines, and upregulates the expression
of Toll-Like Receptor-4 (TLR-4) by phagocytes [9]. Because
of the prevention of p53-dependent apoptosis of activated
macrophages, high concentrations of MIF result in sustained
inﬂammatoryresponses.Therefore,MIFseemstocounteract
the antioxidative eﬀects of TRX. Accordingly, we were
also able to demonstrate signiﬁcantly higher MIF-levels in
patients of the septic group in comparison to patients of
the postoperative or volunteer groups. MIF is secreted by
leukocytes,anditssynthesisisinducedbybacterialendo-and
exotoxins and several proinﬂammatory mediators (Tumor
Necrosis Factor-α/TNF-α, Interferon-γ/IFN-γ, Complement
Factor 5a/C5a). For the acute phase of sepsis, it has been
demonstrated that high plasma levels are harmful and
c o r r e l a t ew i t hs e p s i ss e v e r i t y[ 8]. The neutralization of MIF
results in an attenuation of the inﬂammatory response and
improved survival in experimental sepsis [8, 50]. In the
light of these observations, the relationship between TRX1
and MIF in sepsis is of great interest. To our knowledge,
only little work has been done so far in simultaneously
determining plasma levels of TRX1 and MIF in human
sepsis or septic animal models [49]. In accordance to the
results of Leaver and colleagues [51], we were able to show
raised plasma levels of TRX1 and MIF in patients with
SIRS/sepsis, wherebyplasma levels of TRX1and MIFshowed6 Mediators of Inﬂammation
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Figure 3: Comparison of Macrophage Migration Inhibitory Factor
(MIF) measurements in the volunteer, postoperative, and septic
groups at baseline and at 24 and 48 hours in the septic group.
Concentrations of Macrophage Migration Inhibitory Factor (MIF;
(pg/ml)) were measured from the sera of healthy volunteers
(“Healthy,” n = 18, white box), postoperative patients after major
abdominal surgery (“Post-OP,” n = 28, light grey box), and patients
with sepsis (“Sepsis,” n = 15, dark grey box), at t0 (measured
once for the volunteer group, immediately after surgery for the
postoperative group, and at the time of diagnosis of sepsis for
the sepsis group). In addition, for the septic group, the two other
times of data collection are represented, t24 and t48 for 24 and
48 hours, respectively, after the diagnosis of sepsis. Data in box
plots is given as median, 25th percentile, 75th percentile, and the
1.5 interquartile range. Outliers are shown in form of circles (1.5–3
interquartile ranges above 75th percentile or below 25th percentile)
or rectangles (>3 interquartile ranges above 75th percentile or
below 25th percentile). Abbreviations: MIF, Macrophage Migration
Inhibitory Factor.
a unique correlation. Unfortunately, neither TRX1 nor MIF
showed signiﬁcant diﬀerences between the surviving and
nonsurviving subgroups of the septic patients and therefore
could not be used as an early predictor for survival in
patients with severe sepsis or septic shock. This may be due
to the small cohort of septic patients, so a re-evaluation in a
larger cohort of septic patients needs to be performed. Fur-
thermore, the detailed mechanisms of interaction between
TRX1 and MIF are not yet completely understood. Son et
al. recently suggested that cell surface TRX1 serves as one
of the MIF binding molecules or MIF-receptor components
and inhibits MIF-mediated inﬂammatory signals [52]. As a
possible limitation of this investigation, the signiﬁcant lower
age of healthy volunteers in comparison to the postoperative
group as well as the septic group has to be stated. At
last, we are not able to estimate exactly the inﬂuence
of patients’ age on the redox marker measurements in
the diﬀerent study groups. Unfortunately, many previously
published investigations dealing with these parameters are
aﬄicted with the same problem [47, 51]. Nevertheless, it
remains unlikely that the factor age might have considerably
inﬂuenced the presented study results, since TRX1 and MIF
0
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0 2000 4000 6000
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Figure 4: Strong correlation between TRX1 and MIF plasma
levels in patients with severe sepsis or septic shock at the onset
of sepsis syndrome. The scatter plot visualizes concentrations of
Macrophage Migration Inhibitory Factor (MIF; (pg/ml)) as well as
accompanying concentrations of Thioredoxin-1 (TRX1; (ng/ml))
frompatients with severe sepsis or septic shock at the onset of sepsis
syndrome (t0) (“Sepsis,” n = 15, black circles). Abbreviations: MIF,
Macrophage Migration Inhibitory Factor; TRX1, Thioredoxin-1.
plasma levels showed signiﬁcant diﬀerences in patients of
the same age (postoperative cohort versus septic cohort)
and were comparable in patients of signiﬁcant diﬀerent ages
(healthy volunteers versus postoperative cohort). Due to the
positive correlations of TRX1 and MIF, our investigation
supports a linked role of these two mediators in the patho-
physiology of sepsis. This has important implications for
further research on the pathogenesis of severe sepsis or septic
shock.
5. Conclusions
In summary, our results suggest that substances involved in
the redox homeostasis (e.g., TRX1, MIF) represent central
hubs in the septic inﬂammatory response, as assessed by
signiﬁcantly elevated plasma levels of these mediators in
patients with severe sepsis or septic shock. Proinﬂammatory/
∼oxidative and anti-inﬂammatory/∼oxidative agents show a
high correlation in order to maintain a redox homeostasis
and to avoid harmful eﬀects of an excessive inﬂamma-
tory/oxidative response. For this reason, the detailed mecha-
nismsoftheTRX1andMIFinteraction,aswellastheiruseas
possibletargetsfortherapeuticmanipulation,representareas
for further research.
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